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Abstract
Many studies using animals clarify that glial cell line-derived neurotrophic factor (GDNF) has
strong neuroprotective and neurorestorative effects on dopaminergic neurons. Several pilot studies
clarified the validity of continuous intraputaminal GDNF infusion to patients with Parkinson’s
disease (PD), although a randomized controlled trial of GDNF therapy published in 2006 resulted
in negative outcomes, and controversy remains about the efficacy and safety of the treatment. For
a decade, our laboratory has investigated the efficacy and the most appropriate method of GDNF
administration using animals, and consequently we have obtained some solid data that correspond
to the results of clinical trials. In this review, we present an outline of our studies and other
key studies related to GDNF, the current state of the research, problems to be overcome, and
predictions regarding the use of GDNF therapy for PD in the future.
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arkinson’s disease (PD) is characterized by the 
degeneration of dopaminergic neurons in the 
nigrostriatal system [1,  2].  The established treat-
ment for PD is oral L-DOPA [3,  4] and stereotaxic 
surgeries such as deep brain stimulation [5].  In 
Europe and the United States,  fetal nigral cell trans-
plantation has also been performed in PD patients. 
However,  after 2 randomized clinical trials revealed 
insuﬃ  cient functional recovery in older patients and 
delayed dyskinesia in some patients [6,  7],  the 
momentum for exploring a new therapy for PD using 
stem cells or neurotrophic/growth factor increased. 
Stem cell therapy might be the most useful therapeu-
tic option for PD,  because recent molecular/cell bio-
logical development enables us to make dopaminergic 
neurons from embryonic stem cells [8] or mesenchy-
mal stem cells [9].  However,  there are many prob-
lems in terms of safety and eﬃ  ciency as well as ethi-
cal issues to be resolved ; these problems should be 
overcome before this therapy is clinically applied. 
Neurotrophic/growth factor might also be useful for 
PD.  Since Dr. Lin and her colleagues isolated glial 
cell line-derived neurotrophic factor (GDNF) and 
demonstrated that GDNF enhances the survival and 
morphological diﬀ erentiation of dopaminergic neu-
rons [10],  many laboratory studies have examined 
GDNF therapy as a treatment for various diseases of 
the central nervous system (CNS),  including stroke 
[11],  spinal cord injury [12],  traumatic brain injury 
[13] and neurodegenerative diseases,  such as PD [14, 
15] and amyotrophic lateral sclerosis (ALS) [16]. 
P
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GDNF is considered to be one of the strongest neu-
roprotectants for dopaminergic neurons.  Based on 
the successful results of animal experiments,  clinical 
trials were performed for PD patients using GDNF. 
In this review,  recent ﬁ ndings with regard to GDNF 
therapy are described,  as is the current status of 
GDNF therapy for PD patients.
Therapeutic Eﬀ ects of GDNF on
 PD Model of Animals
　 Mechanisms of GDNF therapy.　 GDNF,  a 
member of the transforming growth factor ｹ [10], 
is known to demonstrate neuroprotective and neuro-
restorative eﬀ ects on dopaminergic neurons [17ﾝ20] 
through a heterodimetric receptor complex consisting 
of a transmembrane receptor tyrosine kinase,  Ret, 
and the ligand binding component GDNF-family 
receptor ｸ1 (GFRｸ1) [21,  22].  Cell survival/death 
decisions are determined in part through the activa-
tion of a speciﬁ c intracellular signaling cascade,  such 
as the phosphatidylinositide 3 kinase pathway and the 
mitogen-activated protein kinase pathway [21,  23].
　　Key experiments using GDNF for PD model 
of animals.　 Dr.  Hebb and his colleagues demon-
strated that GDNF enhanced the survival of fetal rat 
dopaminergic neurons for the purpose of transplanta-
tion [18].  GDNF therapy by ventricular infusion 
using an osmotic minipump suppressed the neuronal 
degeneration induced by 6-OHDA [19,  24].  In vivo 
gene delivery of GDNF was also a feasible neuropro-
tective strategy for PD [20].  Recently the impor-
tance of transplanted cells as neurotrophic/growth 
factor suppliers has been re-evaluated [25]. 
Similarly,  GDNF secreted by transplanted cells is 
considered to be one of the reasons that therapeutic 
eﬀ ects are achieved by cell transplantation [26,  27]. 
Our group demonstrated that the implantation of 
encapsulated GDNF-secreting cells into 6-OHDA-
lesioned striatum resulted in protective eﬀ ects on 
dopaminergic neurons [28ﾝ30].  Rats receiving an 
implantation of GDNF-secreting cells at 2 weeks 
after 6-OHDA lesions were induced showed more 
neurorestorative eﬀ ects compared to those receiving 
the implantation 4 weeks after 6-OHDA lesions were 
induced [29].  After this study was completed,  we 
performed a new experiment using earlier timing for 
the implantation ; that is,  the implantation was per-
formed simultaneously with and at 1,  2,  and 4 weeks 
after the 6-OHDA lesions were induced,  with 
GFRｸ1 expression in the striatum and substantia 
nigra being evaluated at 1 and 2 weeks after the 
6-OHDA lesions were induced [30].  In the study, 
the earlier implantation of GDNF resulted in a more 
improved behavioral score and better preserved 
dopaminergic neurons with a higher expression level 
of GFRｸ1 [30],  thus revealing that GDNF-
responsive ﬁ bers and neurons are necessary for 
GDNF therapy.
　　Advantages of GDNF therapy using encap-
sulated cell transplantation.　 Encapsulated cell 
transplantation has been clinically used for the treat-
ment of diseases arising from hormone-producing 
organs like the pancreas and parathyroid [31,  32]. 
For the CNS diseases,  encapsulated ciliary neuro-
trophic factor (CNTF)-producing cells and chromaﬃ  n 
cells were transplanted into ALS patients and 
patients with severe chronic pain,  respectively [33, 
34].  As described in the previous section,  encapsu-
lated cell transplantation was used to administer 
GDNF to a PD model of rats in our laboratory. 
Encapsulated cell transplantation has many advan-
tages [35] (Fig.  1).  1) Various neurotransmitters or 
neurotrophic factors can be produced continuously 
from encapsulated cells with tailored properties. 
Cells inside the capsule survive with a suﬃ  cient sup-
ply of nutrients and oxygen through the semiperme-
able membrane and are capable of secreting factors 
outwards.  2) Few immune reactions and no immuno-
logical rejection arise because the cells inside are 
protected by a stiﬀ  envelope.  The molecular sieve 
prevents immunocompetent cells from invading the 
capsule and attacking the donor cells.  3) 
Tumorigenesis does not occur because the donor 
cells stay inside the capsule.  4) The capsule can be 
removed from the transplanted brain when problems 
arise after transplantation.  5) Various cells including 
immortalized cell lines can be transplanted safely as 
surviving donors with almost no ethical problems. 
Compared to the infusion using a pump system,  the 
delivery of freshly made factor with no degradation 
and the absence of a need for pump implantation are 
the advantages of encapsulated cell transplantation. 
A single administration of GDNF was useful for the 
PD model of rats [36],  and delayed short-term 
GDNF administration close to the substantia nigra 
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protected against neuronal degeneration [37]. 
However,  the study revealed that short-term GDNF 
administration could not achieve a long-term rescue 
of the nigral cells.  Indeed,  PD is slowly progressive, 
so a long-lasting eﬀ ect is desirable.  In our recent 
study,  we used encapsulated cells secreting fresh 
GDNF at about 20 ng per day for 2 months in vivo 
[30].  Although the dose was relatively low compared 
to some studies,  intraparenchymal continuous infu-
sion appeared to be more eﬀ ective than intraventricu-
lar infusion [38].
Current State of GDNF Therapy
 for PD Patients
　　Success of intraputaminal GDNF infusion 
in PD patients.　 Based on the successful results 
of the animal experiments described above,  a clinical 
trial using GDNF was begun for PD patients. 
However,  the initial several studies demonstrated 
that the intraventricular injection of GDNF did not 
improve the motor scores of PD patients and caused 
many side eﬀ ects such as nausea,  anorexia,  vomiting, 
weight loss,  hyponatremia,  paresthesias including 
Lehrmitte signs and psychotic manifestations [39, 
40].  The researchers considered that the unexpected 
poor results might be due to inappropriate GDNF 
delivery,  because intraputaminal GDNF infusion to 
aged non-human primates ameliorated the behavioral 
score and the metabolism of dopamine with no prob-
lematic side eﬀ ects [41].  Dr.  Gill and his colleagues 
then reported successful results using intraputaminal 
GDNF infusion in 2003 [42].  The direct administra-
tion of GDNF into the putamen of ﬁ ve PD patients 
improved the patients’ Uniﬁ ed Parkinson’s Disease 
Rating Scale (UPDRS) score in the oﬀ -medication 
state after 1 year with no serious side eﬀ ects.  More-
over,  medication-induced dyskinesia was reduced by 
64ｵ and was not observed in the oﬀ -medication state 
during chronic GDNF delivery [42].  After this 
report,  several groups demonstrated the therapeutic 
eﬀ ect of GDNF on PD patients [43ﾝ45].  Dr.  Gill’s 
group in England continued GDNF infusion for 2 
years and reported good outcomes with no side 
eﬀ ects [44].  The same group demonstrated neuro-
pathological evidence that GDNF infusion for 43 
months caused sprouting of dopaminergic ﬁ bers in 
accordance with functional recovery [43].  In Ken-
tucky,  Dr.  Slevin and his colleagues demonstrated 
that even unilateral GDNF infusion achieved bilat-
eral improvement of motor functions with transient 
paresthesia in 20ｵ of patients [45].
　　Recent controversy and hope surrounding 
GDNF therapy for PD patients.　 However in 
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Fig. 1　　Scheme of encapsulated cells.  Capsules are made with semipermeable membrane.  Oxygen and nutrition can freely move 
into the capsule,  although antibodies and immunocompetent cells cannot pass through the membrane.  In addition,  the trophic factor or 
neurotransmitter secreted from cells inside the capsule can be expanded around the capsule.
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2005,  Amgen,  the company holding the patents on 
GDNF therapy for PD,  brought the clinical trial 
using GDNF to a halt,  but not the pre-clinical and 
basic research [46,  47].  The main reasons for this 
decision were the negative results of the recent ran-
domized controlled trial and the neutralizing anti-
GDNF antibody found in 3 of 34 patients [48].  The 
latter was a factor even though these three patients 
were asymptomatic and the bioactivity and toxicity of 
the neurtralizing antibody remains to be explored.  In 
addition,  cerebellar lesions were found in monkeys 
receiving a high dose of GDNF [46,  48].  These 
results and the decision of Amgen disappointed the 
patients and researchers involved in this study,  and 
there has been ﬁ erce controversy over the decision 
[49ﾝ52].  However,  it is too early to conclude that 
GDNF therapy is not feasible for PD patients,  as 
such a conclusion would be based on just one study 
including several problems (an atypically younger 
patient population,  and the GDNF dose and delivery 
system used in this study) as described in Dr. 
Baker’s letter [53].  As many new experimental 
treatments are unlikely to be unqualiﬁ ed successes at 
ﬁ rst,  we should re-consider the potential problems in 
the studies of GDNF therapy.  If the administration 
of GDNF for a long time causes problems,  we should 
investigate the long-term outcomes for patients 
receiving the GDNF infusion for just a few months. 
Alternatively,  the eﬀ ectiveness of intermittent 
administration of GDNF could be investigated. 
There are many questions to be answered before this 
research direction is abandoned.  Recently,  MRI 
analyses of nine PD patients with GDNF therapy 
revealed no cerebellar lesions in accord with a lack 
of cerebellar dysfunctions [54].  Continuous and 
steady eﬀ orts like the study from Kentucky are 
required,  although the future of GDNF therapy is 
still unknown.
　　GDNF secreted from transplanted cells in 
PD patients.　 Recently the importance of trans-
planted cells as suppliers of trophic factors has come 
to light.  In clinical application,  autologous cells are 
relatively safe for patients and present almost no 
ethical issues ; they are considered to be strong 
potential candidates for therapies for PD [55ﾝ57]. 
Dr.  Arjona reported that 6 patients with advanced 
PD underwent bilateral transplantation of autologous 
carotid body cell aggregates into the striatum [55]. 
Bilateral intrastriatal transplantation was performed 
in six PD patients with both pre- and post-transplant 
(18 months) evaluations.  No patients demonstrated 
side eﬀ ects,  including dyskinesia.  In addition,  5 of 6 
patients showed ameliorated UPDRSⅢ in their oﬀ -
state.  Carotid body-grafted Parkinsonian animals 
showed a nigrostriatal dopaminergic neurorestora-
tion,  at least partially resulting from GDNF secre-
tion from the grafted cells [58].  In our laboratory, 
the therapeutic eﬀ ects of genetically engineered 
GDNF-secreting neural stem cells are also being 
explored using a PD model of animals to enhance the 
therapeutic eﬀ ects of the neural stem cell itself.
Conclusions
　　Key animal experiments,  including our recent 
ﬁ ndings related to GDNF and clinical trials of 
GDNF therapy for PD patients,  are described in 
this review.  The future of GDNF therapy is uncer-
tain,  although GDNF has strong neuroprotective and 
neurorestorative eﬀ ects.  Steady and continuous 
eﬀ orts are required to elucidate the potencies of 
GDNF and its potential contribution to PD patients.
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